Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05349695
Other study ID # 001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2022
Est. completion date May 2024

Study information

Verified date April 2022
Source Studie- & Opleidingscentrum Neurochirurgie Virga Jesse
Contact Mark Plazier, MD,PhD
Phone +3211335511
Email mark.plazier@jessazh.be
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The PROSTIM study is an ongoing prospective, multicentric and observational clinical study. Patients are recruited in three different centers in Eastern Belgium from May 2018 onwards. This real-world data collection approaches the outcome assessment of daily medical practice. A hierarchical cluster analysis is used to identify significant patient clusters based on the Visual Analogue Scale (VAS), Oswestry disability index (ODI), Pain Vigilance and Awareness Questionnaire (PVAQ), Pain Catastrophizing Scale (PCS) and EuroQol with five dimensions for health-related quality of life (EQ-5D). Patient clusters will be assessed on the change in biopsychosocial variables after six weeks, three and twelve months. Secondary outcomes include the comparison of pain medication use, SCS parameters, treatment satisfaction and return to work.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date May 2024
Est. primary completion date May 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male/female over 18 years old. - Chronic intractable back and/or leg pain (PSPS T2), refractory to conservative treatment measures. - Positive recommendation after multidisciplinary assessment including psychiatric assessment. - Patients are capable of giving written informed consent. Exclusion Criteria: - Negative recommendation after multidisciplinary assessment (ex. psychiatric disorders). - Insufficient improvement during trial period. - Previous SCS implantation. - Removal due to complication (infection, loss of function,...) - Surgical contraindication (infection of surgical site, coagulation disorders,..) - Pregnancy.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Spinal cord stimulation
Eligible patients will undergo a SCS trial period for three weeks (as legally defined by the reimbursement authorities). The leads can be placed both surgically of percutaneously with an external trial stimulator. Surgical implantation of an implanted pulse generator (IPG) is performed if the patient achieves at least 50% pain reduction and a reduced pain medication use (reimbursement requirements) during the trial period. Subsequently, the implanted devices are programmed to the optimal parameters in collaboration with a nurse specialized in SCS treatment. The patients are educated on the use of the patient programmer.

Locations

Country Name City State
Belgium Jessa Hospital Hasselt
Belgium Sint-Franciscus Ziekenhuis Heusden-Zolder
Belgium St. Trudo Ziekenhuis Sint-Truiden

Sponsors (2)

Lead Sponsor Collaborator
Studie- & Opleidingscentrum Neurochirurgie Virga Jesse Medtronic

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Back pain Visual analogue scale back (0-10) 3 weeks
Primary Leg pain Visual analogue scale back (0-10) 3 weeks
Primary Back pain Visual analogue scale back (0-10) 6 months
Primary Leg pain Visual analogue scale back (0-10) 6 months
Primary Back pain Visual analogue scale back (0-10) 12 months
Primary Leg pain Visual analogue scale back (0-10) 12 months
Primary Disability Oswestry Disability Index, ODI (0-100) 3 weeks
Primary Disability Oswestry Disability Index, ODI (0-100) 6 months
Primary Disability Oswestry Disability Index, ODI (0-100) 12 months
Primary Health-related quality of life EQ-5D-3L 3 weeks
Primary Health-related quality of life EQ-5D-3L 6 months
Primary Health-related quality of life EQ-5D-3L 12 months
Secondary Pain medication WHO classification and/or the use of neuropathic pain medication 3 weeks
Secondary Pain medication WHO classification and/or the use of neuropathic pain medication 6 months
Secondary Pain medication WHO classification and/or the use of neuropathic pain medication 12 months
Secondary Spinal cord stimulation type Type of spinal cord stimulation amongst different patient clusters 3 weeks
Secondary Spinal cord stimulation type Type of spinal cord stimulation amongst different patient clusters 6 months
Secondary Spinal cord stimulation type Type of spinal cord stimulation amongst different patient clusters 12 months
Secondary Satisfied with current treatment Yes/No question 3 weeks
Secondary Satisfied with current treatment Yes/No question 6 months
Secondary Satisfied with current treatment Yes/No question 12 months
Secondary Rate of return to work % of patients returning to work or daily activities 3 weeks
Secondary Rate of return to work % of patients returning to work or daily activities 6 months
Secondary Rate of return to work % of patients returning to work or daily activities 12 months
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain